Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05898477 · ClinicalTrials.gov registry record
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
A clinical trial of Lymphoma and Hemophagocytic Lymphohistiocytoses, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT05898477: Recruiting study of Lymphoma and Hemophagocytic Lymphohistiocytoses, sponsored by University of Alabama at Birmingham.
NCT05898477 is a study of Lymphoma and Hemophagocytic Lymphohistiocytoses that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 2,000 participants, above the 477-participant average among 299 other Lymphoma trials with a reported enrollment target (319% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05898477, a study of Lymphoma and Hemophagocytic Lymphohistiocytoses, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
Primary Outcome
The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival.
Conditions Studied
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2028-07 |
What NCT05898477 shows while recruiting
NCT05898477 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 477-participant average among 299 other Lymphoma trials with a reported enrollment target (319% higher).
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT05898477 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT05898477 about?
NCT05898477 is a clinical study titled "Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis". The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
What is the current status of trial NCT05898477?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2023-05-01. Estimated completion is 2028-07.
What conditions does trial NCT05898477 study?
This clinical trial studies the following conditions: Lymphoma, Hemophagocytic Lymphohistiocytoses.
Who is sponsoring clinical trial NCT05898477?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05898477 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05898477's enrollment target sits among peer trials
2,000 5th of 299 higher than 295 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI